✦ LIBER ✦

Long-lasting suppression of Paget’s disease activity with cyclical tiludronate treatment

✍ Scribed by J.D Ringe; O Wiedemann

Book ID: 117808851
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 21 KB
Volume: 24
Category: Article
ISSN: 8756-3282
DOI: 10.1016/s8756-3282(99)00066-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Paget’s disease with tiludr

Treatment of Paget’s disease with tiludronate

✍ W.D Fraser 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 21 KB

Long lasting suppression of disease live

Long lasting suppression of disease liver activity may lead to a reversibility of cirrhosis

✍ J. Serpaggi; F. Carnot; B. Nalpas; J. Lagneau; J. Guechot; H. Fontaine; A. Valle 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Changes of bone remodelling surfaces and

Changes of bone remodelling surfaces and bone structure in Paget's disease following long-term treatment with calcitonin

✍ G. R. Delling; A. Schulz; R. Ziegler 📂 Article 📅 1976 🏛 Springer 🌐 English ⚖ 118 KB

Serum osteoprotegerin and its ligand in

Serum osteoprotegerin and its ligand in Paget's disease of bone: Relationship to disease activity and effect of treatment with bisphosphonates

✍ L. Alvarez; P. Peris; N. Guañabens; S. Vidal; I. Ros; F. Pons; X. Filella; A. Mo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Long-term benefits of rivastigmine in de

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study

✍ Werner Poewe; Erik Wolters; Murat Emre; Marco Onofrj; Chuanchieh Hsu; Sibel Teki 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

## Abstract In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24‐week double‐blind placebo‐controlled trial. Our objective was to determine wh

OUTCOME OF PATIENTS WITH GRAVES' DISEASE

OUTCOME OF PATIENTS WITH GRAVES' DISEASE AFTER LONG-TERM MEDICAL TREATMENT GUIDED BY TRIIODOTHYRONINE (T3) SUPPRESSION TEST

✍ M. YAMAMOTO; Y. TOTSUKA; I. KOJIMA; N. YAMASHITA; K. TOGAWA; N. SAWAKI; E. OGATA 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 558 KB